Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
15 Cards in this Set
- Front
- Back
|
ETDRS
|
CSME criteria: 1) RT w/in 500 microns; 2) lipid w/in 500 w/ assoc RT; 3) >1DD w/in 1DD of fovea
|
|
|
DRS
|
high PDR criteria: 3 or more of the following:
1) Any NV of fundus; 2) NV w/in 1 DD of disc 3) Pre-retinal heme 4) NV of moderate extent |
|
|
DCCT (DM control & complication trial)
|
Type 1 DM, BS control decreases risk of DR; results in PDR & ME in 3 & 5 yrs respectively
|
|
|
BVOS
|
grid60% better than 20/40; control34% better than 20/40; PRP helps reduce NV (if present) or helps prevent NV for nonperfusion >5DD however, since NV only develops in 31% w/ >5DD ischemia, wait for NV to do PRP; conclusion: grid if >20/40 & >3mo; only applies to pts w/ perfused maculae (ischemic macula pts were excluded from study)
|
|
|
CVOS
|
Grid—improved edema but not VA, therefore, not recommended; >10DA ischemia 25-30% NV w/in 3 yrs; PRP reduced incidence of NV but was not statistically significant; PRP reduced efficacy of future lasers if needed
|
|
|
Endophthalmitis vitrectomy study
|
if ≥HM, T&I=vtx; if <HM vtx better than T&I; no difference w/ systemic Abx; eligibility: presumed bact endoph >6 wk PO CE
|
|
|
ANCHOR
|
IVit Ranizumab=11 letters better than PDT for acute classic AMD
|
|
|
Macular photocoagulation study
|
argon decreased vision loss or at least preserved visual function for CNV subfoveal (worse VA but better visual function), juxtafoveal (1-199um from fovea) & extrafoveal (>200um from Fovea)
|
|
|
subfoveal new CNV studay from MPS
|
eligibility: small lesions w/ VA<20/80 (Best candidate for laser= VA <20/125 (lesions <1DA) or <20/200 (lesions <2DA), No benefit=lesions >3DA & VA >20/200); short & long term, contrast sensitivity preserved by laser; short term-VA & reading speed decreased in tx group (improved long term)
|
|
|
silicone oil study group
|
C3F8 & oil were much more successful than SF6 for PVR RD reattachment tamponade
|
|
|
HEDS
|
HSV: stromal keratitis: Topical steroids reduced persistence or progression; delayed steroids slowed resolution but did not help long term visual outome; gradual taper of steroids; viroptic does not help
|
|
|
OHTS
|
risk factors for OHTCOAG: age, race, IOP, ON anatomy, CCT
|
|
|
CIGTS (collaborative initial glaucoma tx study)
|
Rx vs Sx on long term progression; Sx group=more likely to lose VA & VF in first few years but after 4 years, groups were similar
|
|
|
IONDT (ischemic optic neuropathy decompression trial)
|
30% w/ NAION w/ ON sheath decompression had improvement of 3+ lines @ 6 months; 40% on observation group improved by 3+ lines; surgery=higher risk of loss of 3+ lines (24% vs 12%)
|
|
|
ONTT (optic neuritis tx trial)
|
PO steroids had no significant improvement than control group & increase recurrence rate; IV + PO steroidsfaster recovery & slight improvement over control
|
